Dr. Gust Bardy, president of the Seattle Institute for Cardiac Research and lead investigator of the Home Automated External Defibrillator Trial (HAT), published in the New England Journal of Medicine, will discuss the use of automated external defibrillators, both at home and in public locations, as a strategy to reduce mortality rates among patients who are at higher risk for sudden cardiac death.
AEDs: Limiting Rates of Sudden Cardiac Death
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Dr. Gust Bardy, president of the Seattle Institute for Cardiac Research and lead investigator of the Home Automated External Defibrillator Trial (HAT), published in the New England Journal of Medicine, will discuss the use of automated external defibrillators, both at home and in public locations, as a strategy to reduce mortality rates among patients who are at higher risk for sudden cardiac death.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
HF Management for Patients with Comorbid Conditions
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?